Non-adherence to medicine is a major concern for the UK health economy. The National Institute for Health and Care Excellence (NICE) estimates that £4 billion of medicine is currently not used correctly, and as a result, biopharma must strive to understand the varying types and causes of non-adherence.

The local care pathway should be under focus if biopharma is to tackle nonadherence. By using real patient and treatment data to analyze core pathway frailties that contribute to non-adherence. solutions can be developed to help improve that core pathway, and more critically, explore what motivates individual patients to adhere. Where a patient is on the treatment pathway is also vital, as recently diagnosed patients have different needs to those who have lived for several years with a disease. Patient support services can then be designed to respond to those different needs.